FTGT results on patient nos. 1, 5, and 2. (A) The fluorogenic thrombin generation curve for patient no. 1 before and throughout the study period. There is a clear high peak in the baseline sample that most likely reflects the exogenous recombinant FVIII that the patient self-administered 7 days before the start of the study. The peak of thrombin generation steadily declines from that time point on and it is possible that this exogenous factor masked any contribution to overall thrombin generation that the endogenous factor synthesized under the influence of gentamicin could have made. (B) The FTGT for patient no. 5 before and throughout the study period. There is a peak of thrombin generation in the day-2 pretreatment (PT) sample that correlates with the drop in aPTT and rise in FIX level seen in Figure 2. (C) The FTGT for patient no. 2 before and throughout the study period. There is an increase in thrombin generation throughout the study period that correlates with the rise in the FIX antigen level (Figure 3) but is not reflected in the aPTT or FIX one-stage assay. RFU indicates relative fluorescence units.